Kbc Group Nv Travere Therapeutics, Inc. Transaction History
Kbc Group Nv
- $32.2 Billion
- Q1 2025
A detailed history of Kbc Group Nv transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 4,187 shares of TVTX stock, worth $88,555. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,187Holding current value
$88,555% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
100MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$188 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$162 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$159 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$106 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$101 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.36B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...